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Abstract
Background—The decision to pursue fertility preservation (FP) after a cancer diagnosis is
complex. We examined the prevalence of high decisional conflict and specific factors that
influence this decision using the decisional conflict scale (DCS).
Methods—The FIRST project is a web-based survey of female cancer survivors (age 18–44
years) who have undergone gonadotoxic treatment. We evaluated the association between recalled
decisional conflict and referral to FP counseling, demographic, socioeconomic and cancer
variables.
Results—Of 208 participants, 115 subjects (55%) had scores consistent with high decisional
conflict (DCS score >37.5 out of 100) and 43 (21%) were in the moderate range (25 – 37.5). In
unadjusted analysis, high decisional conflict was associated with lack of referral to FP
consultation, not undergoing FP treatment, concerns regarding cost, length of survivorship, lower
income, education, partner status and cancer type. In multivariable analysis, significantly higher
prevalence of high decisional conflict was observed in participants who were not referred for FP
consultation (prevalence ratio [PR] 1.25 (95% confidence interval [CI] 1.06–1.47), as well as in
participants who reported cost of FP services to be prohibitive (PR 1.16 (95% CI 1.03–1.31).
Prevalence of high DCS was lower for women who underwent FP treatment (PR 0.67 (95% CI
0.52–0.86).
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Conclusions—In this study of female young adult cancer survivors, the majority recall
significant decisional conflict about FP at cancer diagnosis. Increasing access to FP via referral for
counseling and cost reduction may decrease decisional conflict about FP for young patients
struggling with cancer and fertility decisions.
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Introduction
In an era of increasing survival rates for young cancer patients, there is growing emphasis on
post-treatment quality of life1. For many female young adult survivors, the ability to have
biological children is central to their quality of life2, 3. Because many cancer treatments have
the potential to be gonadotoxic, newly diagnosed cancer patients are advised to consider
their desire for future fertility and fertility preservation (FP) options prior to cancer
treatments4, 5. Despite recommendations from the American Society of Clinic Oncology and
the American Society of Reproductive Medicine in support of early discussion of treatment-
related infertility and referral to a reproductive specialist if desired5, very few female young
adult patients undergo FP counseling and treatment6–8.
Decisions about undergoing FP counseling and treatment are complex, occurring in a time
of turmoil closely following a new cancer diagnosis. There may be a great deal of decisional
conflict regarding FP prior to cancer treatment. Factors that may contribute to the stress
surrounding FP decisions include unmet information needs on FP options, uncertainty
regarding the impact of planned cancer treatment on future reproduction, safety concerns,
time constraints and financial considerations9. Reproductive specialists are able to provide
personalized information about options, risks and financial support resources, provided that
newly diagnosed patients are referred appropriately for consultation.
The Decisional Conflict Scale (DCS) is a tool that approximates the degree of uncertainty
that individuals encounter when faced with challenging medical decisions9–12. In other
medical fields, high DCS scores have been associated with greater emotional distress,
delayed decision-making, vacillation between decisions, future regret, and placement of
blame on providers13, 14. Recent research with female young adult cancer survivors
indicates high decisional conflict associated with FP decisions15, 16.
The goal of this study is to identify factors associated with decisional conflict about FP
using data from a prospective cohort study of reproductive outcomes in female young adult
cancer survivors. We hypothesized that the majority of female cancer survivors would report
experiencing high decisional conflict with regard to decisions about FP prior to cancer
treatment. As decisional conflict may result from unmet informational needs, we further
hypothesized that referrals to FP consultation would be associated with decreased decisional
conflict.
Materials and Methods
The Fertility Information Research Study (FIRST) is an ongoing prospective cohort study
examining reproductive outcomes in female young adult cancer survivors. Inclusion criteria
for the FIRST project are women age 18 to 44 years at study enrollment with a personal
history of cancer. We conducted a cross-sectional study approved by the institutional review
board at the University of California, San Diego using FIRST data. For this analysis, we
included FIRST participants who underwent potentially gonadotoxic cancer therapy
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including systemic chemotherapy, pelvic radiation and/or gynecological surgery. FIRST
participants were recruited from social media outreach through young adult cancer survivor
advocacy groups, six university-based fertility preservation programs, and other sources
including patient referrals. Participants were recruited from 44 states in the U.S. and
completed the enrollment telephone- or web-based questionnaire between May, 2011 and
October, 2012. The study questionnaire included questions on demographic, cancer,
medical, and reproductive history, and recalled decision conflict about fertility preservation.
Subjects were asked if they felt that FP consultation and/or treatment was cost prohibitive.
Subjects reported if they had been referred for a FP consultation and whether they
underwent any FP treatments including: GnRH agonists such as GnRH agonists, embryo
banking, egg banking, surgical oophorpexy or other.
Decisional Conflict
Decisional conflict was assessed using a modified version of the validated DCS17. This tool
included 16 items, each using a five-point Likert response format. Final scores range from 0
(low decisional conflict) to 100 (high decisional conflict). Scores > 37.5 indicate high levels
of decisional conflict, scores 25 – 37.5 represent a moderate degree of conflict, while scores
< 25 indicate confidence in decisions made17. Study participants were asked to ‘think about
the choice they made about fertility preservation’ when answering the DCS items.
Statistical Analysis
Descriptive statistics were calculated as frequencies and percentages for categorical data and
median and interquartile ranges (IQR) for continuous data. We used Wilcoxon Rank Sum
tests to evaluate differences in DCS scores by demographic, cancer, and FP referral and
treatment characteristics. A Pearson Correlation coefficient was used to evaluate the
correlation between time since cancer diagnosis and DCS. Because of the high prevalence of
DCS > 37.5 in the cohort, log-binomial regression was used to estimate unadjusted
prevalence ratios (PR) and 95% confidence intervals (95% CI) for high DCS, as well as
those adjusted for potential confounding factors18. We developed three separate
multivariable models to examine the association between the outcome variable, high DCS
about fertility preservation, and three explanatory variables: 1) referral for FP consultation;
2) uptake of FP treatment; and 3) cost concerns related to FP services (consultation or
treatment). Because of the likely causal influences of FP consultation and cost concerns on
uptake of treatment, and in order to avoid over-adjustment19 or induced bias20, we modeled
these variables separately. We included potential confounders, variables that were
significantly associated with the outcome and explanatory variable, in each model.
Additionally, a sensitivity analysis to assess potential recall bias was performed by
evaluating unadjusted models in subsets of the data defined by the time between cancer
diagnosis and completing the survey. Statistical analyses were conducted using SAS
statistical software v9.2 (Cary, NC).
Results
Of 237 FIRST participants, 29 were excluded because they did not receive gonadatoxic
therapy, leaving 208 for analysis. Table 1 summarizes participant characteristics. Median
age of participants was 31 years (IQR 26–35 years). Breast cancer was the most common
cancer type. Few participants (6.3%) reported having no form of health insurance.
One hundred three participants (49.5%) reported referral for fertility preservation
consultation. Sixty-four percent of these participants were referred by their primary
oncologist, while the remainder was referred by other physicians or were self-referred.
Eighty-five women (41%) underwent FP treatment including egg, embryo, or ovarian tissue
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banking, or treatment with GnRH agonist. The median DCS score of the study population
was 41.1 (IQR 25.0 – 57.0). One hundred fifteen participants (55.3%) had scores consistent
with high decisional conflict (>37.5 out of 100).
Table 2 demonstrates univariate associations with DCS scores. Participants who were not
referred to FP consultation had significantly higher DCS scores compared to women who
were referred (51.6 [IQR 37.5–64.1] vs. 31.3 [IQR 18.8–43.8]; P<0.0001). DCS scores were
lower in those who underwent FP treatment (P<0.0001). Participants who reported lower
income, lower level of education completed, and not being in a partnered relationship had
higher decisional conflict. Compared to survivors of breast cancer, women reporting other
cancers had higher DCS scores. Longer time since diagnosis was also correlated with higher
scores (rho=0.35, P<0.0001). Subjects who were more than 5 years after cancer were nearly
twice as likely to recall high DCS than women in the first year of survivorship. Age, race,
parity and desire for future fertility were not significantly associated with DCS scores.
Associations between income, education, relationship status, cancer type and each of the FP
explanatory variables were examined. Income was related to both cost concerns and FP
treatment; those with income <$50K were twice as likely to report cost concerns (52% vs.
25%, P<0.0001) and roughly half as likely to have FP treatments, compared to those not
reporting incomes <$50K (23% vs. 41%, P=0.007). Education was unrelated to any of the
FP variables of interest. Relationship status was related to cost concerns and referral for
counseling but not treatment. Those reporting being partnered were less likely to report cost
concerns (42% vs. 66%, P=0.001) and more likely to be referred for consultation (61% vs.
54%, P<0.0001) than those reporting not being partnered. While cancer type was not
associated with cost concerns or FP treatment, participants with breast cancer were more
likely to be referred for consultation than those with other cancers (66% vs. 23%, P=0.001).
Table 3 depicts both models of high DCS adjusted only for time since diagnosis and for
models adjusting for confounding factors in addition to time since diagnosis. In models of
high DCS adjusted only for time since diagnosis, non-referral was associated with a nearly
two-fold increased likelihood of high DCS (PR 1.83, P<0.0001). Undergoing FP treatment
was associated with significantly lower likelihood of high DCS (PR 0.53, P<0.0001).
Reported cost concerns was also associated with high DCS (PR 1.23, P=0.006).
In models adjusting for potential confounding factors and time since diagnosis, estimates for
each of the FP explanatory variables were attenuated, but remained statistically significant
(Table 3). Women who were not referred to FP consultations were significantly more likely
to report high decisional conflict (PR 1.25, P=0.009). Those who underwent FP treatment
were less likely to have high decisional conflict (PR 0.67, P=0.001). Finally, women who
felt FP consultation or treatment was cost prohibitive reported more decisional conflict in
these adjusted analyses (PR 1.16, P=0.01). In all adjusted models, income, partner status,
time since diagnosis, and cancer type were no longer significantly associated with high
decisional conflict.
Results of a sensitivity analysis to assess potential effects of time since diagnosis as a
potential source of recall bias on estimates are shown in Table 4. For this assessment,
unadjusted models of high DCS were run to assess associations with non-referral for FP
consultation, uptake of FP treatment and cost concerns in the entire cohort (n=208), in the
subset who completed the survey within 3 years of diagnosis (n=123) and in the subset who
completed the survey within 1 year of diagnosis (n=47). Estimates were similar across these
subsets for all three variables considered.
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In this study, we examine decisional conflict regarding fertility preservation prior to cancer
treatment in a cohort of female young adult cancer survivors. As hypothesized, the study
found that the majority of women recalled moderate to high decisional conflict about their
FP decisions prior to gonadotoxic cancer treatment. Young women who were not referred to
FP counseling or for whom cost of either counseling or treatment was prohibitive
experienced significantly higher rates of decisional conflict. These results identify
modifiable factors that could reduce decisional conflict and improve care of female young
adult cancer patients.
Decisional conflict is a state of uncertainty about the course of action to take. Increased
decisional conflict may result from making choices that have high stakes in terms of risks
and rewards, ones that are rushed or have time limits, that encompass moral judgments and
have uncertainty of outcomes and when there may be anticipated regret about the positive
aspects of rejected options17. The decision to pursue FP services prior to cancer treatment
involves many of these qualities and is extremely time sensitive. Concordantly, in this study,
a large portion of reproductive aged women recalled having had moderate (21%) to severe
(55%) conflict about their FP decisions.
These findings are consistent with the limited data on decisional conflict in female cancer
patients regarding fertility interventions. In a decision aid intervention study in newly
diagnosed young breast cancer patients, mean DCS scores on fertility intervention reported
at diagnosis was 48.3, with 63% of participants reporting high decisional conflict16. Follow
up of this cohort demonstrated lower DCS scores at 12 months, even in those who did not
receive the decision aid intervention (mean DCS score 29.3 without intervention versus 14.7
with intervention)21. In the current study, high DCS scores (median 41.4) were recalled by
survivors of a variety of common YA cancers (breast cancer constituted 32% of the cohort),
even at an average of 2.4 years after diagnosis. These results highlight the challenges faced
by female young adult cancer patients regarding FP decisions at cancer diagnosis.
In multivariate analyses, we found three factors associated with increased decisional
conflict: lack of referral to FP consultation, concerns that FP services were cost prohibitive,
and not undergoing fertility preservation treatment. During consultations, reproductive
specialists aim to provide in depth counseling on not only FP procedures, but also risks to
long-term reproductive health associated with cancer treatment. In this cohort, FP
consultation referral was associated with less decisional conflict. This is consistent with
studies suggesting that without specialized FP counseling, comprehension of FP options
may be compromised, and that more patients may be interested in FP treatment if knowledge
was increased16, 22. Moreover, in a recent web-based survey completed by female cancer
survivors who had undergone FP consultation, the median DCS was 29.7, which is similar to
the scores in the current study among women who had undergone FP counseling (31.3)15.
Finally, data support that discussion of FP options alone, even if patients do not undergo FP
treatment, may allow patients to feel more comfortable with their decisions and future
fertility outcomes. Counseling may facilitate educated decisions as well as provide an
opportunity for patients to cope with potential treatment-related infertility and for providers
to manage expectations23.
Currently, most specialized FP counseling occurs by consultations with reproductive
specialists. However, the emergence of trained patient navigators and decision aids to
inform decisions about FP at the time of cancer diagnosis may offer an alternative, more
cost-effective approach to delivering FP information16. As these services are developed, it is
pertinent to note we found higher decisional conflict in participants with lower income and
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less formal education. This finding highlights the potential relationship between health
literacy levels and FP decision-making. Effective educational strategies will need to be
developed to adequately address needs of diverse populations.
One-third of participants reported that costs for FP services were prohibitive, and those for
whom costs were prohibitive experienced higher decisional conflict. Cost as a barrier to FP
treatment has remained a prominent issue as FP awareness has increased but insurance
coverage for FP treatments remains severely limited. In a recent multi-institutional study
examining decisional conflict after FP counseling, 41% of female survivors stated that ‘cost’
was the most influential factor in their decision making22. Improving access and financial
support for FP is modifiable and continues to evolve at the organizational (Livestrong
Sharing Hope Program, Ferring heartbeat program) and state health policy levels.
Finally, interestingly, higher decisional conflict on FP was observed in women with longer
durations of survivorship, a finding opposite of those of Peate and colleagues16. We
speculate that this finding may reflect priorities shifting from cancer treatment to
survivorship and stronger consideration of adverse late effects as participants recall the
decisions they made on FP. However, further longitudinal studies are needed to validate this
finding.
Strengths of this study include a moderately large, geographically diverse sample of female
young adult cancer survivors and ascertainment of FP outcomes. This study also utilized
recruitment though social media outreach to reach a unique subset of survivors that may not
have otherwise been represented. This study is also the largest to date to assess decisional
conflict related to FP choices and to investigate modifiable factors to decrease that conflict.
This study has several limitations. Patients self-selected to be part of the FIRST project and
may have done so because they had especially positive or negative feelings regarding their
FP choices. Moreover, participants tended to be Caucasian, report moderate to high income,
and were highly educated – these characteristics need to be taken into account when
considering the generalizability of the study. Our results suggest that young survivors who
undergo FP treatment have lower decisional conflict than those who do not. While
reassuring, this cross-sectional study design limits our ability to make causal inferences.
This finding may also represent a recall bias, where those who underwent FP treatment
recalled conflict regarding FP treatment decisions differently than those who did not
undergo treatment. Because decisional conflict was assessed after decisions were made, and
possibly after the reproductive outcome of gonadotoxic treatment was known, it is possible
that satisfaction with either undergoing FP treatment or post-treatment fertility influenced
their recalled decisional conflict. It is reassuring that in sensitivity analysis, we found similar
magnitudes of association between high decisional conflict and FP variables across duration
of survivorship. However, prospective studies in a diverse group of female young adult
cancer patients from diagnosis forward are needed to assess decisional conflict
longitudinally.
The majority of female young adult cancer survivors in this study recalled significant
decisional conflict related to their decisions about FP at the time of their cancer diagnosis.
As many young patients will be at risk of loss of fertility with cancer treatment, it is critical
to identify modifiable risk factors associated with decisional conflict to inform the design of
effective interventions to improve quality of care and to optimize fertility and parenthood
options for young survivors.
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Table 1
Characteristics of FIRST participants (n=208)
Median (IQR) or N (%)
Age (years) (n=207) 31.0 (26.0–35.0)
Race (n=205):
    Caucasian 161 (78.5%)
    African American 6 (2.9%)
    Asian 11 (5.4%)
    Other 27 (13.0%)
Income:
    <$50,000 71 (34.2%)
    ≥$50,000 90 (43.3%)
    Declined to answer 47 (22.6%)
Education: < college 39 (18.7%)
Partnered relationship status 120 (57.7%)
Nulliparous 132 (63.5%)
Desire for future fertility 168 (80.8%)
Cancer type:
    Breast 67 (32.2%)
    Hodgkin’s Lymphoma 41 (19.7%)
    Gynecologic (cervix, ovary, uterine) 23 (11.1%)
    Non-Hodgkin’s Lymphoma 21 (10.1%)
    Leukemia 16 (7.7%)
    Other 40 (19.2%)
Years since cancer diagnosis (n=207) 2.44 (1.10–5.08)
No referral for FP consultation 105 (50.5%)
Underwent FP treatment 85 (40.9%)
Cost prohibitive:
    FP consultation 64 (30.8%)
    FP treatment 60 (28.8%)
    FP services (consultation or treatment) 71 (34.1%)
Recruitment source:
    Social media 119 (57.2%)
    Clinic-based 56 (26.9%)
    Other 33 (15.9%)
DCS score 41.4 (25.0 – 57.0)
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Median (IQR) or N (%)
    Low ( < 25) 50 (24.0%)
    Moderate (25 – 37.5) 43 (20.7%)
    High (> 37.5) 115 (55.3%)
Legend: IQR – interquartile range; FP – fertility preservation; DCS – decisional conflict scale













Mersereau et al. Page 11
Table 2






Age >30 years 37.5 45.3 0.09
Race: Caucasian 42.2 37.5 0.39
Income <$50,0001 53.1 35.9 0.002
Education < college 50.0 39.1 0.02
Partnered relationship status 35.9 50.0 0.01
Nulliparous 40.6 43.0 0.91
Desire for future fertility 40.6 50.0 0.10
Cancer type: Breast 35.9 45.3 0.01
No referral for FP consultation 51.6 31.3 < 0.0001
Underwent FP treatment 26.6 50.0 < 0.0001
FP services cost prohibitive3 56.3 32.8 <0.0001
Legend: DCS – decisional conflict scale; FP – fertility preservation
1
Income was analyzed as a three level variable (‘≥$50,000’, ‘<$50,000’, or ‘declined to answer’). Only the comparison of ‘<$50,000’ compared to




Includes FP consultation and/or treatment
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Table 3
Prevalence ratios (95% CI) from models of high decisional conflict (DCS Score > 37.5) adjusted for time











    No referral for FP consultation 1.83 (1.37, 2.44) 1.25 (1.06 – 1.47) - -
    Underwent FP treatment 0.53 (0.39, 0.71) - 0.67 (0.52 – 0.86) -
    FP services cost prohibitive3 1.23 (1.09, 1.38) - - 1.16 (1.03 – 1.31)
Demographic variables
    Income < $50,0002 1.40 (1.13, 1.75) 1.14 (0.95 – 1.37) 1.12 (0.89 – 1.40) 1.05 (0.91 – 1.23)
    Partnered relationship status 0.76 (0.62, 0.93) 0.93 (0.81 – 1.07) 0.90 (0.75 – 1.07) 0.97 (0.87 – 1.09)
    Cancer type: Breast 0.79 (0.57, 1.08) 0.98 (0.81 – 1.19) 0.93 (0.73 – 1.18) 0.95 (0.82 – 1.09)
Legend: DCS – decisional conflict scale; FP– fertility preservation
1
Fully adjusted models included the FP variable, income, relationship status, cancer type and log-transformed time since diagnosis
2
Income was analyzed as a three level variable (‘≥$50,000’, ‘<$50,000’, or ‘decline to answer’). The PR for ‘decline to answer’ compared to the
reference level of ‘≥$50,000’ was approximately equal to 1 and not statistically significantly different
3
Includes FP consultation and/or treatment
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